TNFRSF25 and graft versus host disease: Activation of DR3 signaling has shown treatment efficacy on multiple inflammatory diseases, such as EAE, lung inflammation, and graft-versus-host diseases (GVHD)6,8–10, therefore sometimes leading to contradictory conclusions on the effect of TL1A/DR3 with TL1A/DR3-blockade studies.